Last month, the U.S. Food and Drug Administration (the “FDA”) announced in a Declaratory Order the resolution of the shortage of semaglutide ...

By Alberto Alerigi SAO PAULO (Reuters) -Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide ...

A coalition of over 20 leading health organizations is calling on the U.S. Food & Drug Administration (FDA) to enforce federal regulations on compounded we ...

Hypera plans to introduce a generic version of semaglutide in Brazil following patent expiration in 2026. The company is optimistic about market growth despite potential price impacts. Analysts ...

Copycat versions of Eli Lilly's diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They're ...

According to a recent study, tirzepatide and semaglutide offer long-term health benefits but are not cost-effective.

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

A class action lawsuit was filed against Novo Nordisk A/S (NVO) by Levi & Korsinsky on January 24, 2025. The plaintiffs ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

A new study has found that a once-weekly injection of semaglutide, a medication originally developed for diabetes and weight ...

The global weight-loss drug market is expected to reach $150 billion in the next decade. By 2026, semaglutide (the active ...